Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia

Technology appraisal guidance
Reference number: TA425
Published: 21 December 2016

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 227 KB)

Published:

23 January 2017

Final appraisal determination

Final appraisal determination
Final appraisal determination document (PDF 376 KB)

Published:

17 November 2016
Committee papers (PDF 1.17 MB)

Published:

17 November 2016

Invitation to participate

Final scope (PDF 101 KB)

Published:

19 July 2016
Final matrix (PDF 96 KB)

Published:

19 July 2016

Appeal

: Appeal letter (PDF 1.41 MB)

Published:

02 September 2011
: Scrutiny letter (PDF 270 KB)

Published:

12 September 2011
: Appeal letter (PDF 741 KB)

Published:

20 October 2017
: Response to scrutiny letter (PDF 504 KB)

Published:

26 September 2011
: Appeal letter (PDF 316 KB)

Published:

29 August 2011
: Final scrutiny letter (PDF 223 KB)

Published:

29 September 2011
: Scrutiny letter (PDF 249 KB)

Published:

12 September 2011
: Response to scrutiny letter (PDF 419 KB)

Published:

21 September 2011
: Appeal letter (PDF 257 KB)

Published:

20 October 2017
: Final scrutiny letter (PDF 279 KB)

Published:

30 September 2011
: Response to scrutiny letter (PDF 1.76 MB)

Published:

03 October 2011
Appeal decision TA241 & TA251 (PDF 236 KB)

Published:

30 January 2012

Final appraisal determination

Final appraisal determination document TA241 (PDF 306 KB)

Published:

11 August 2011
Committee papers TA241 (PDF 3.76 MB)

Published:

11 August 2011